CHMA - Chiasma shares rise 6% on positive Mycapssa data in hormonal disorder

Chiasma (CHMA) perks 6% premarket after announcing positive top-line data from its global Phase 3 MPOWERED non-inferiority clinical trial comparing Mycapssa (oral octreotide capsules) to long-acting injectable somatostatin analogs (SSAs) for maintenance of biochemical response in patients with acromegaly, a hormonal disorder in adults in which the pituitary gland produces too much growth hormone. The study met its primary non-inferiority endpoint. 91% of Mycapssa patients maintained insulin-like growth factor 1 (IGF-1) response (95% CI = 80%, 97%) compared to 100% on injectable SSAs (95% CI = 91%, 100%).Response was defined as the time-weighted average of IGF-1 <1.3 x upper limit of normal ((ULN)) during the 9-month randomized, controlled treatment ((RCT)) phase.Mean IGF-1 in the MYCAPSSA cohort at the beginning and end of the RCT phase was 0.9 × ULN and 0.9 × ULN, respectively, compared to 0.8 × ULN and 0.8 × ULN, respectively, in the injectable SSA cohort. The company plans to

For further details see:

Chiasma shares rise 6% on positive Mycapssa data in hormonal disorder